To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Buy and TMO is a Buy. BIO [@Medical Specialties] is valued at $12.43B. TMO’s [@Medical Specialties] market capitalization is $220.81B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $6.22B. Long-Term Analysis It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red). BIO’s FA Score shows that 0 FA rating(s) are green whileTMO’s FA Score has 2 green FA rating(s). According to our system of comparison, TMO is a better buy in the long-term than BIO. Short-Term Analysis It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past. If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal. BIO’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s). According to our system of comparison, TMO is a better buy in the short-term than BIO. BIO (@Medical Specialties) experienced а +1.91% price change this week, while TMO (@Medical Specialties) price change was +3.23% for the same time period. The average weekly price growth across all stocks in the @Medical Specialties industry was +2.41%. For the same industry, the average monthly price growth was 0.00%, and the average quarterly price growth was 0.00%. Reported Earning Dates BIO is expected to report earnings on Feb 08, 2023. TMO is expected to report earnings on Jan 31, 2023. Industries' Descriptions @Medical Specialties (+2.41% weekly) Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets. TMO($221B) has a higher market cap than BIO($12.4B). TMO has higher P/E ratio than BIO: TMO (31.65) vs BIO (3.64). TMO YTD gains are higher at: -16.311 vs. BIO (-44.537). TMO has higher annual earnings (EBITDA): 11.8B vs. BIO (-7.68B). TMO has more cash in the bank: 2.92B vs. BIO (1.85B). BIO has less debt than TMO: BIO (1.38B) vs TMO (29.2B). TMO has higher revenues than BIO: TMO (44.2B) vs BIO (2.81B). BIOTMOBIO / TMOCapitalization12.4B221B6%EBITDA-7.68B11.8B-65%Gain YTD-44.537-16.311273%P/E Ratio3.6431.6512%Revenue2.81B44.2B6%Total Cash1.85B2.92B63%Total Debt1.38B29.2B5% BIOTMOOUTLOOK RATING1..1002434VALUATIONovervalued / fair valued / undervalued1..10082Overvalued79OvervaluedPROFIT vs RISK RATING1..100606SMR RATING1..1008578PRICE GROWTH RATING1..1005945P/E GROWTH RATING1..1006729SEASONALITY SCORE1..100n/a50 Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry. TMO's Valuation (79) in the Medical Specialties industry is in the same range as BIO (82). This means that TMO’s stock grew similarly to BIO’s over the last 12 months. TMO's Profit vs Risk Rating (6) in the Medical Specialties industry is somewhat better than the same rating for BIO (60). This means that TMO’s stock grew somewhat faster than BIO’s over the last 12 months. TMO's SMR Rating (78) in the Medical Specialties industry is in the same range as BIO (85). This means that TMO’s stock grew similarly to BIO’s over the last 12 months. TMO's Price Growth Rating (45) in the Medical Specialties industry is in the same range as BIO (59). This means that TMO’s stock grew similarly to BIO’s over the last 12 months. TMO's P/E Growth Rating (29) in the Medical Specialties industry is somewhat better than the same rating for BIO (67). This means that TMO’s stock grew somewhat faster than BIO’s over the last 12 months. 1 DaySTOCK / NAMEPrice $Chg $Chg %TMPO4.220.27+6.84%Tempo Automation HoldingsHCC39.082.32+6.31%Warrior Met CoalRIBT1.140.03+2.70%RiceBran TechnologiesDRD6.970.14+2.05%DRDGOLD LtdLSI105.80-0.43-0.40%Life Storage A.I.dvisor indicates that over the last year, BIO has been closely correlated with DHR. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then DHR could also see price increases. Ticker / NAMECorrelationTo BIO1D PriceChange %BIO100%+0.24%DHR - BIO76%Closely correlated-0.11%BRKR - BIO75%Closely correlated-1.12%TMO - BIO75%Closely correlated-0.28%MTD - BIO73%Closely correlated-0.28%A - BIO72%Closely correlated-0.29%More ACCESS TO ALLAI ROBOTSBuy nowfor only $180 per month ($250)OR subscribe for a year andsave 50% ($90 per month) More